February 15, 2017
Surrozen secures $33 million through Series A financing to fund its research of Wnt signaling in regeneration
A newly formed biopharmaceutical company based in San Francisco, USA, has ensured funds for unlocking research of the therapeutic potential of Wnt signaling, a key for stem-cell maintenance and tissue regeneration.